Get started
TG THERAPEUTICS INTG THERAPEUTICS INTG THERAPEUTICS IN

TG THERAPEUTICS IN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NKB2 chart


Full chart

NKB2 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.70 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
260.226
Basic EPS (TTM)
0.147 CHF
Net income (FY)
‪21.24 M‬ CHF
Revenue (FY)
‪298.80 M‬ CHF
Shares float
‪141.43 M‬
Beta (1Y)
0.63

Employees


Employees (FY)
338
Change (1Y)
+74 +28.03%
Revenue / Employee (1Y)
‪884.03 K‬ CHF
Net income / Employee (1Y)
‪62.83 K‬ CHF

About TG Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael Sean Weiss
Website
tgtherapeutics.com
Headquarters
Morrisville
Founded
1993
FIGI
BBG00LVGH2Q2
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NKB2 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as NKB2.

Frequently Asked Questions


The current price of NKB2 is 29.600 CHF — it has decreased by −0.26% in the past 24 hours. Watch TG THERAPEUTICS IN stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange TG THERAPEUTICS IN stocks are traded under the ticker NKB2.
NKB2 stock has fallen by −0.26% compared to the previous week, the month change is a −7.34% fall, over the last year TG THERAPEUTICS IN has showed a 89.28% increase.
We've gathered analysts' opinions on TG THERAPEUTICS IN future price: according to them, NKB2 price has a max estimate of 48.59 CHF and a min estimate of 9.72 CHF. Watch NKB2 chart and read a more detailed TG THERAPEUTICS IN stock forecast: see what analysts think of TG THERAPEUTICS IN and suggest that you do with its stocks.
NKB2 reached its all-time high on Jun 25, 2021 with the price of 35.801 CHF, and its all-time low was 0 CHF and was reached on Jun 25, 2021. View more price dynamics on NKB2 chart.
See other stocks reaching their highest and lowest prices.
NKB2 stock is 0.26% volatile and has beta coefficient of 0.63. Track TG THERAPEUTICS IN stock price on the chart and check out the list of the most volatile stocks — is TG THERAPEUTICS IN there?
Today TG THERAPEUTICS IN has the market capitalization of ‪4.92 B‬, it has decreased by −6.71% over the last week.
Yes, you can track TG THERAPEUTICS IN financials in yearly and quarterly reports right on TradingView.
TG THERAPEUTICS IN is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NKB2 earnings for the last quarter are 0.14 CHF per share, whereas the estimation was 0.14 CHF resulting in a −4.55% surprise. The estimated earnings for the next quarter are 0.14 CHF per share. See more details about TG THERAPEUTICS IN earnings.
TG THERAPEUTICS IN revenue for the last quarter amounts to ‪98.25 M‬ CHF, despite the estimated figure of ‪91.43 M‬ CHF. In the next quarter, revenue is expected to reach ‪103.95 M‬ CHF.
NKB2 net income for the last quarter is ‪21.19 M‬ CHF, while the quarter before that showed ‪3.29 M‬ CHF of net income which accounts for 544.41% change. Track more TG THERAPEUTICS IN financial stats to get the full picture.
No, NKB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 338 employees. See our rating of the largest employees — is TG THERAPEUTICS IN on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG THERAPEUTICS IN EBITDA is ‪38.33 M‬ CHF, and current EBITDA margin is 12.83%. See more stats in TG THERAPEUTICS IN financial statements.
Like other stocks, NKB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG THERAPEUTICS IN stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG THERAPEUTICS IN technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG THERAPEUTICS IN stock shows the strong buy signal. See more of TG THERAPEUTICS IN technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.